Dysautonomia

From Wikipedia, the free encyclopedia
(Redirected from Autonomic dysfunction)

Template:Short description Template:Cs1 config Template:Infobox medical condition (new)

Dysautonomia, autonomic failure, or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does not work properly. This condition may affect the functioning of the heart, bladder, intestines, sweat glands, pupils, and blood vessels. Dysautonomia has many causes, not all of which may be classified as neuropathic.[1] A number of conditions can feature dysautonomia, such as Parkinson's disease, Long COVID, multiple system atrophy, dementia with Lewy bodies,[2] Ehlers–Danlos syndromes,[3] autoimmune autonomic ganglionopathy and autonomic neuropathy,[4] HIV/AIDS,[5] mitochondrial cytopathy,[6] pure autonomic failure, autism, and postural orthostatic tachycardia syndrome.[7]

Diagnosis is made by functional testing of the ANS, focusing on the affected organ system. Investigations may be performed to identify underlying disease processes that may have led to the development of symptoms or autonomic neuropathy. Symptomatic treatment is available for many symptoms associated with dysautonomia, and some disease processes can be directly treated. Depending on the severity of the dysfunction, dysautonomia can range from being nearly symptomless and transient to disabling and/or life-threatening.[8]

Signs and symptoms

Dysautonomia, a complex set of conditions characterized by autonomic nervous system (ANS) dysfunction, manifests clinically with a diverse array of symptoms of which postural orthostatic tachycardia syndrome (POTS) stands out as the most common.[7]

The symptoms of dysautonomia, which are numerous and vary widely for each person, are due to inefficient or unbalanced efferent signals sent via both systems.[medical citation needed] Symptoms in people with dysautonomia include:

Page Template:Div col/styles.css has no content.

Causes

File:Vincristine3DanBS.gif
Vincristine

Dysautonomia may be due to inherited or degenerative neurologic diseases (primary dysautonomia)[1] or injury of the autonomic nervous system from an acquired disorder (secondary dysautonomia).[9][12] Its most common causes include:

Script error: No such module "Template wrapper".

In the sympathetic nervous system (SNS), predominant dysautonomia is common along with fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis, raising the possibility that such dysautonomia could be their common clustering underlying pathogenesis.[26]

In addition to sometimes being a symptom of dysautonomia, anxiety can sometimes physically manifest symptoms resembling autonomic dysfunction.[27][28][29] A thorough investigation ruling out physiological causes is crucial, but in cases where relevant tests are performed and no causes are found or symptoms do not match any known disorders, a primary anxiety disorder is possible but should not be presumed.[30] For such patients, the anxiety sensitivity index may have better predictivity for anxiety disorders while the Beck Anxiety Inventory may misleadingly suggest anxiety for patients with dysautonomia.[31]

Mitochondrial cytopathies can have autonomic dysfunction manifesting as orthostatic intolerance, sleep-related hypoventilation, and arrhythmias.[6][32][33]

Mechanism

The autonomic nervous system is a component of the peripheral nervous system and comprises two branches: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PSNS). The SNS controls the more active responses, such as increasing heart rate and blood pressure. The PSNS, for example, slows down the heart rate and aids digestion. Symptoms typically arise from abnormal responses of either the sympathetic or parasympathetic systems based on situation or environment.[1][34][24]

Diagnosis

File:Valsalva maneuver.jpg
Valsalva maneuver

Diagnosis of dysautonomia depends on the overall function of three autonomic functions—cardiovagal, adrenergic, and sudomotor. A diagnosis should, at a minimum, include measurements of blood pressure and heart rate while lying flat and after at least three minutes of standing. The best way to make a diagnosis includes a range of testing, notably an autonomic reflex screen, tilt table test, and testing of the sudomotor response (ESC, QSART or thermoregulatory sweat test).[35]

Additional tests and examinations to diagnose dysautonomia include:

Script error: No such module "Template wrapper".

Tests to elucidate the cause of dysautonomia can include:

Vegetative-vascular dystonia and Da Costa's syndrome

Particularly in the Soviet and post-Soviet medical literature,[36][37] a subtype of dysautonomia that particularly affects the vascular system has been called Vegetative-vascular dystonia [ru; de].[38] The term "vegetative" reflects an older name for the autonomic nervous system: the vegetative nervous system.[citation needed] While rooted in earlier concepts of neurasthenia, the diagnosis was crystallized by G.F. Lang [ru]'s 'neurogenic theory' to describe a functional precursor to essential hypertension:[39] a stress-induced autonomic dysregulation that Soviet physicians observed en masse amidst the devastation of the war of annihilation on the Eastern Front.[36]

Despite official recognition by the medical institutions in the USSR and some other Warsaw-pact countries (and their successor countries), it has also been described as a form of culture-bound syndrome.[36]

A similar form of this disorder has been historically noticed in various wars, including the Crimean War and American Civil War, and among British troops who colonized India. This disorder was called "irritable heart syndrome" (Da Costa's syndrome) in 1871 by American physician Jacob DaCosta.[40]

Management

File:Cimetidine-xtal-3D-balls.png
The H2 receptor antagonist cimetidine

Treatment of dysautonomia can be difficult; since it is made up of many different symptoms, a combination of drug therapies is often required to manage individual symptomatic complaints. In the case of autoimmune neuropathy, treatment with immunomodulatory therapies is done. If diabetes mellitus is the cause, control of blood glucose is important.[9] Treatment can include proton-pump inhibitors and H2 receptor antagonists used for digestive symptoms such as acid reflux.[41]

To treat genitourinary autonomic neuropathy, medications may include sildenafil (a guanine monophosphate type-5 phosphodiesterase inhibitor). To treat hyperhidrosis, anticholinergic agents such as trihexyphenidyl or scopolamine can be used. Intracutaneous injection of botulinum toxin type A can also be used in some cases.[42]

Transvascular autonomic modulation, a procedure similar to balloon angioplasty, is not approved in the United States to treat autonomic dysfunction.[43]

Prognosis

The prognosis of dysautonomia depends on several factors; people with chronic, progressive, generalized dysautonomia in the setting of central nervous system degeneration such as Parkinson's disease or multiple system atrophy generally have poorer long-term prognoses. Dysautonomia can be fatal due to pneumonia, acute respiratory failure, or sudden cardiopulmonary arrest.[1] Autonomic dysfunction symptoms such as orthostatic hypotension, gastroparesis, and gustatory sweating are more frequently identified in mortalities.[44]

See also

Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c d e Page Module:Citation/CS1/styles.css has no content."Dysautonomia". NINDS. Archived from the original on 2016-12-02. Retrieved 2012-04-03.
  2. ^ a b Page Module:Citation/CS1/styles.css has no content.Palma JA, Kaufmann H (March 2018). "Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies". Mov Disord (Review). 33 (3): 372–90. doi:10.1002/mds.27344. PMC 5844369. PMID 29508455.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Castori M, Voermans NC (October 2014). "Neurological manifestations of Ehlers-Danlos syndrome(s): A review". Iranian Journal of Neurology. 13 (4): 190–208. PMC 4300794. PMID 25632331.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Imamura M, Mukaino A, Takamatsu K, Tsuboi H, Higuchi O, Nakamura H, Abe S, Ando Y, Matsuo H, Nakamura T, Sumida T, Kawakami A, Nakane S (February 2020). "Ganglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases". Int J Mol Sci (Review). 21 (4): 1332. doi:10.3390/ijms21041332. PMC 7073227. PMID 32079137.
  5. ^ Page Module:Citation/CS1/styles.css has no content.McIntosh RC (August 2016). "A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy". Clin Auton Res (Review). 26 (4): 287–94. doi:10.1007/s10286-016-0366-6. PMID 27395409. S2CID 20256879.
  6. ^ a b Page Module:Citation/CS1/styles.css has no content.Kanjwal K, Karabin B, Kanjwal Y, Saeed B, Grubb BP (October 2010). "Autonomic dysfunction presenting as orthostatic intolerance in patients suffering from mitochondrial cytopathy". Clinical Cardiology. 33 (10): 626–629. doi:10.1002/clc.20805. ISSN 1932-8737. PMC 6653231. PMID 20960537.
  7. ^ a b c Page Module:Citation/CS1/styles.css has no content.Peltier AC (June 2024). "Autonomic Dysfunction from Diagnosis to Treatment". Prim Care. 51 (2): 359–373. doi:10.1016/j.pop.2024.02.006. PMID 38692780.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Iodice V, Kimpinski K, Vernino S, Sandroni P, Fealey RD, Low PA (June 2009). "Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy". Neurology. 72 (23): 2002–8. doi:10.1212/WNL.0b013e3181a92b52. PMC 2837591. PMID 19506222.
  9. ^ a b c d e f g h i j k l Page Module:Citation/CS1/styles.css has no content."Autonomic Neuropathy Clinical Presentation: History, Physical, Causes". emedicine.medscape.com. Retrieved 2016-02-21.
  10. ^ a b c d e f g h Page Module:Citation/CS1/styles.css has no content."Autonomic Neuropathy. Information about AN. Patient | Patient". Patient info. Retrieved 2016-02-21.
  11. ^ a b c d e f g h i MedlinePlus Encyclopedia: Autonomic neuropathy
  12. ^ Page Module:Citation/CS1/styles.css has no content.Kirk KA, Shoykhet M, Jeong JH, Tyler-Kabara EC, Henderson MJ, Bell MJ, Fink EL (August 2012). "Dysautonomia after pediatric brain injury". Developmental Medicine and Child Neurology. 54 (8): 759–64. doi:10.1111/j.1469-8749.2012.04322.x. PMC 3393822. PMID 22712762.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Tateno F, Sakakibara R, Aiba Y, Ogata T (2020). "Alcoholism mimicking multiple system atrophy: a case report". Clin Auton Res. 30 (6): 581–584. doi:10.1007/s10286-020-00708-y. PMID 32607716. S2CID 220260700.
  14. ^ Page Module:Citation/CS1/styles.css has no content.Davies K, Ng WF (2021). "Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome". Frontiers in Immunology. 12. doi:10.3389/fimmu.2021.702505. PMC 8350514. PMID 34381453.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Imrich R, Alevizos I, Bebris L, Goldstein DS, Holmes CS, Illei GG, Nikolov NP (2015). "Predominant Glandular Cholinergic Dysautonomia in Patients with Primary Sjögren's Syndrome". Arthritis & Rheumatology. 67 (5): 1345–1352. doi:10.1002/art.39044. PMC 4414824. PMID 25622919.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Dysautonomia: What It Is, Symptoms, Types & Treatment".
  17. ^ Page Module:Citation/CS1/styles.css has no content."Dysautonomia in Sjögren's". 26 October 2023.
  18. ^ Page Module:Citation/CS1/styles.css has no content.De Wandele I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F, De Paepe A, Calders P (August 2014). "Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome". Seminars in Arthritis and Rheumatism. 44 (1): 93–100. doi:10.1016/j.semarthrit.2013.12.006. PMID 24507822.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Zaeem Z, Siddiqi ZA, Douglas W, Zochodne DW (2019). "Autonomic involvement in Guillain-Barré syndrome: an update". Clin Auton Res. 29 (3): 289–299. doi:10.1007/s10286-018-0542-y. PMID 30019292. S2CID 49868730.
  20. ^ Page Module:Citation/CS1/styles.css has no content.Sakakibara R, Uchiyama T, Kuwabara S, Mori M, Ito T, Yamamoto T, Awa Y, Yamaguchi C, Yuki N, Vernino S, Kishi M, Shirai K (2009). "Prevalence and mechanism of bladder dysfunction in Guillain-Barre Syndrome". Neurourol Urodyn. 28 (5): 432–437. doi:10.1002/nau.20663. PMID 19260087. S2CID 25617551.
  21. ^ Page Module:Citation/CS1/styles.css has no content.Paliwal VK, Garg RK, Gupta A, Tejan N (2020). "Neuromuscular presentations in patients with COVID-19". Neurological Sciences. 41 (11): 3039–3056. doi:10.1007/s10072-020-04708-8. PMC 7491599. PMID 32935156.
  22. ^ Page Module:Citation/CS1/styles.css has no content.Astin R, Banerjee A, Hall CN (2023). "Long COVID: mechanisms, risk factors and recovery". Experimental Physiology. 108 (1): 12–27. doi:10.1113/EP090802. PMC 10103775. PMID 36412084.
  23. ^ Page Module:Citation/CS1/styles.css has no content."Paraneoplastic syndromes of the nervous system". Mayo Clinic. Retrieved 13 September 2016.
  24. ^ a b c d Acob, Lori Mae Yvette. (2021). Autonomic Nervous System Dysfunction – Concussion Alliance. Retrieved 21 September 2021, from https://www.concussionalliance.org/autonomic-nervous-system-dysfunction
  25. ^ Page Module:Citation/CS1/styles.css has no content.Aiba Y, Sakakibara R, Tateno F, Shimizu N (May 2021). "Orthostatic hypotension possibly caused by vincristine". Neurology and Clinical Neuroscience. 9 (4): 365–366. doi:10.1111/ncn3.12517. S2CID 235628396.
  26. ^ Page Module:Citation/CS1/styles.css has no content.Martínez-Martínez LA, Mora T, Vargas A, Fuentes-Iniestra M, Martínez-Lavín M (April 2014). "Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies". Journal of Clinical Rheumatology. 20 (3): 146–50. doi:10.1097/RHU.0000000000000089. PMID 24662556. S2CID 23799955.
  27. ^ Page Module:Citation/CS1/styles.css has no content.Soliman K, Sturman S, Sarkar PK, Michael A (2010). "Postural orthostatic tachycardia syndrome (POTS): a diagnostic dilemma". British Journal of Cardiology. 17 (1): 36–9.
  28. ^ Page Module:Citation/CS1/styles.css has no content.Ackerman K, DiMartini AF (2015). Psychosomatic Medicine. Oxford University Press, Incorporated. ISBN 978-0-19-932931-1.
  29. ^ Page Module:Citation/CS1/styles.css has no content.Carr A, McNulty M (2016-03-31). The Handbook of Adult Clinical Psychology: An Evidence Based Practice Approach. Routledge. ISBN 978-1-317-57614-3.
  30. ^ Page Module:Citation/CS1/styles.css has no content.Tasman A, Kay J, First MB, Lieberman JA, Riba M (2015-03-30). Psychiatry, 2 Volume Set. John Wiley & Sons. ISBN 978-1-118-84547-9.
  31. ^ Page Module:Citation/CS1/styles.css has no content.Raj V, Haman KL, Raj SR, Byrne D, Blakely RD, Biaggioni I, Robertson D, Shelton RC (March 2009). "Psychiatric profile and attention deficits in postural tachycardia syndrome". Journal of Neurology, Neurosurgery, and Psychiatry. 80 (3): 339–44. doi:10.1136/jnnp.2008.144360. PMC 2758320. PMID 18977825.
  32. ^ Page Module:Citation/CS1/styles.css has no content.Emanuel H, Ahlstrom K, Mitchell S, McBeth K, Yadav A, Oria CF, Da Costa C, Stark JM, Mosquera RA, Jon C (2021-04-01). "Cardiac arrhythmias associated with volume-assured pressure support mode in a patient with autonomic dysfunction and mitochondrial disease". Journal of Clinical Sleep Medicine. 17 (4): 853–857. doi:10.5664/jcsm.9024. ISSN 1550-9397. PMC 8020692. PMID 33231166.
  33. ^ Page Module:Citation/CS1/styles.css has no content.Parikh S, Gupta A (March 2013). "Autonomic dysfunction in epilepsy and mitochondrial diseases". Seminars in Pediatric Neurology. 20 (1): 31–34. doi:10.1016/j.spen.2013.01.003. ISSN 1558-0776. PMID 23465772.
  34. ^ Page Module:Citation/CS1/styles.css has no content."Autonomic Nervous System — National Library of Medicine". PubMed Health. National Center for Biotechnology Information. Retrieved 2016-02-21.[dead link]
  35. ^ a b c d e f g h i Page Module:Citation/CS1/styles.css has no content.Mustafa HI, Fessel JP, Barwise J, Shannon JR, Raj SR, Diedrich A, Biaggioni I, Robertson D (January 2012). "Dysautonomia: perioperative implications". Anesthesiology. 116 (1): 205–15. doi:10.1097/ALN.0b013e31823db712. PMC 3296831. PMID 22143168.
  36. ^ a b c Page Module:Citation/CS1/styles.css has no content.Beliaeva A (2019-04-03). "The case of vegetovascular dystonia: inventing the most common Soviet disease". Canadian Slavonic Papers. 61 (2): 146–163. doi:10.1080/00085006.2018.1563452. ISSN 0008-5006.
  37. ^ Page Module:Citation/CS1/styles.css has no content.Loganovsky K (1999). "Vegetative-Vascular Dystonia and Osteoalgetic Syndrome or Chronic Fatigue Syndrome as a Characteristic After-Effect of Radioecological Disaster". Journal of Chronic Fatigue Syndrome. 7 (3): 3–16. doi:10.1300/J092v07n03_02.
  38. ^ Page Module:Citation/CS1/styles.css has no content.Ivanova ES, Mukharliamov FI, Razumov AN, Uianaeva AI (2008). "[State-of-the-art corrective and diagnostic technologies in medical rehabilitation of patients with vegetative vascular dystonia]". Voprosy Kurortologii, Fizioterapii, I Lechebnoi Fizicheskoi Kultury (1): 4–7. PMID 18376477.
  39. ^ Page Module:Citation/CS1/styles.css has no content.Shlyakhto EV, Tsyrlin VA, Kuzmenko NV, Pliss MG (2021-10-09). "Neurophysiological justification of the G. F. Lang hypothesis about the occurrence of essential hypertension". "Arterial'naya Gipertenziya" ("Arterial Hypertension"). 27 (5): 499–508. doi:10.18705/1607-419X-2021-27-5-499-508. ISSN 2411-8524.
  40. ^ Page Module:Citation/CS1/styles.css has no content.Halstead M (2018-01-01). "Postural Orthostatic Tachycardia Syndrome: An Analysis of Cross-Cultural Research, Historical Research, and Patient Narratives of the Diagnostic Experience". Senior Honors Theses & Projects.
  41. ^ Page Module:Citation/CS1/styles.css has no content."H2 Blockers. Reducing stomach acid with H2 Blockers. | Patient". Patient. Retrieved 2016-02-21.
  42. ^ Page Module:Citation/CS1/styles.css has no content."Diabetic Autonomic Neuropathy - Page 9". Medscape.
  43. ^ Page Module:Citation/CS1/styles.css has no content."Safety Alerts for Human Medical Products — Balloon angioplasty devices to treat autonomic dysfunction: FDA Safety Communication — FDA concern over experimental procedures". fda.gov. Archived from the original on September 29, 2019. Retrieved 5 December 2020.
  44. ^ Page Module:Citation/CS1/styles.css has no content.Vinik AI, Maser RE, Mitchell BD, Freeman R (May 2003). "Diabetic autonomic neuropathy". Diabetes Care. 26 (5): 1553–79. doi:10.2337/diacare.26.5.1553. PMID 12716821.

Further reading

Page Template:Refbegin/styles.css has no content.

Template:Medical resources Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Dysautonomia&oldid=256599"